Photo

Photo detail

Arrowhead Pharmaceuticals, led by CEO Christopher Anzalone, is testing RNA molecular technology to treat genetic diseases.

Stories this photo appears in:

Health Care & Biomed: Arrowhead looks to maintain positive momentum

Two companies appear to be heading in opposite directions this year in the biomed and health care space.

Tease photo

Arrowhead Pharmaceuticals Looks to Raise $232 Million

Pasadena biotech firm Arrowhead Pharmaceuticals Inc. set an offering of 4 million shares, seeking to raise up to $232 million to fund operations and strategic investments.

Tease photo

Arrowhead Shares Surge on Big Pharma Acquisition, Positive Earnings

Arrowhead Pharmaceuticals shares surged Nov. 25 as investors reacted to positive earnings and news of a major acquisition in the pharma category.

Tease photo

Arrowhead Pharmaceuticals Inc.

Biggest Gainer in Rank

SPECIAL REPORT: LARGEST PUBLIC COMPANIESMarket Cap: $2.51 billion

Tease photo